OS Therapies Appoints Former Guardant CMO, Eyes 2026 BLA Submission
OS Therapies appointed Craig Eagle, MD, former Guardant Health CMO and Genentech executive, to its strategic advisory board to refine its osteosarcoma regulatory plan and prioritize its oncology pipeline. The company expects a 2026 FDA BLA submission for OST-HER2 after Phase 2b data showed 12-month event-free and overall survival benefits.
1. Strategic Advisory Board Appointment
OS Therapies named Craig Eagle, MD, as the inaugural member of its strategic advisory board. Eagle brings leadership experience as Guardant Health’s Chief Medical Officer and former Genentech and Pfizer oncology executive to guide the company’s osteosarcoma regulatory execution and shape its broader cancer immunotherapy pipeline strategy.
2. Pipeline Prioritization and Regulatory Pathway
The advisory board will assist OS Therapies in refining its submission plan for OST-HER2’s Biologics License Application, anticipated in 2026, following positive Phase 2b results showing 12-month event-free and overall survival benefits in osteosarcoma. The company will also prioritize clinical-stage assets across breast, lung, prostate and HPV-related cancers to maximize shareholder value.